Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

cps 2

Next Previous
Search
Drug Profile

cps 2

Alternative Names: rA2cp248/404-1030 Delta SH genetically stabilised; Recombinant live-attenuated respiratory syncytial virus vaccine - AstraZeneca/NIAID; Respiratory syncytial virus vaccine cps2; RSV vaccine live-attenuated genetically stabilised - AstraZeneca/NIAID

Latest Information Update: 06 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In infants, Prevention) in USA (Intranasal, Drops)
  • 01 Sep 2013 Phase-I clinical trials in Respiratory syncytial virus infections (prevention in infants) in USA (Intranasal)
  • 01 Sep 2013 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for Respiratory syncytial virus infections (prevention) in USA (NCT01968083)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top